Who are JMT101 injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Optimized Treatment (OPT), PF-07275315-dose 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/jmt101-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

JMT101 injection — Competitive Intelligence Brief

JMT101 injection (JMT101 injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Immunology.

phase 3 monoclonal antibody unknown Immunology Small molecule Live · refreshed every 30 min

Target snapshot

JMT101 injection (JMT101 injection) — Shanghai JMT-Bio Inc.. JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
JMT101 injection TARGET	JMT101 injection	Shanghai JMT-Bio Inc.	phase 3	monoclonal antibody	unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Optimized Treatment (OPT)	Optimized Treatment (OPT)	Second Affiliated Hospital of Wenzhou Medical University	marketed	Small molecule	Unknown
PF-07275315-dose 3	pf-07275315-dose-3	Pfizer	marketed	small molecule	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JMT101 injection — Competitive Intelligence Brief. https://druglandscape.com/ci/jmt101-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab